2,5-Dimethoxy-4-trifluoromethylamphetamine
Psychedelic drug of the amphetamine class
2,5-Dimethoxy-4-trifluoromethylamphetamine (also known as DOTFM) is a psychedelic drug of the substituted amphetamines class. It is a derivative of 4-methyl-2,5-dimethoxyamphetamine (DOM) and is structurally related to other compounds in the 2C family and the DOx family.
Chemical structure and properties
DOTFM is chemically classified as a phenethylamine and an amphetamine. Its chemical structure consists of a benzene ring with two methoxy groups (–OCH₃) at the 2 and 5 positions, a trifluoromethyl group (–CF₃) at the 4 position, and an ethylamine chain attached to the benzene ring. The presence of the trifluoromethyl group distinguishes DOTFM from other similar compounds.
Pharmacology
DOTFM acts primarily as a serotonin receptor agonist, particularly at the 5-HT2A receptor, which is believed to be responsible for its psychedelic effects. The exact mechanism of action and the full spectrum of its pharmacological effects are not well understood due to limited research.
Effects
The effects of DOTFM are similar to those of other psychedelic amphetamines, such as DOM and DOB. Users report experiencing altered perceptions, visual distortions, and changes in thought processes. The duration of effects can vary but typically lasts several hours.
Legal status
The legal status of DOTFM varies by country. In some jurisdictions, it may be classified as a controlled substance, while in others, it may not be specifically regulated. Users should be aware of the legal implications of possessing or using DOTFM in their respective regions.
History and research
DOTFM was first synthesized by the American chemist Alexander Shulgin and described in his book PiHKAL (Phenethylamines I Have Known And Loved). Shulgin's work has been instrumental in the study of psychedelic compounds, and DOTFM is one of many substances he explored.
See also
References
External links
Drugs described in PiHKAL |
---|
|
This psychedelic-related article is a stub. You can help WikiMD by expanding it.
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD